BPA for camzyos, pomalyst, and thalomid
Active Awarded Last action
- Contract number
- 36E79726A0010
- Awardee
-
Bristol-Myers Squibb Company UEI UFGKB2B71N12
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 37 $2,235,948 obligated
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Combined order value
- $2,241,763 Current and potential, with all options
- Last date to order 80% complete
- IDV ceiling <1% used
- $2,853,029,285.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
Bristol-Myers Squibb Company, a global biopharmaceutical manufacturer headquartered in Lawrenceville, New Jersey, has been awarded a single-award Blanket Purchase Agreement by the National Acquisition Center with a ceiling value of $2.85 billion and a completion date of January 15, 2027. This BPA covers the supply of three specialized oncology and hematology pharmaceuticals: Camzyos (mavacamten), Pomalyst (pomalidomide), and Thalomid (thalidomide). The contract carries no set-aside designation, reflecting Bristol-Myers Squibb's status as a large pharmaceutical manufacturer. All deliveries are performed through the company's Lawrenceville facility with distribution to Veterans Integrated Service Network 5 in Memphis, Tennessee, supporting the Department of Veterans Affairs' mission to provide advanced cancer treatments to eligible veterans.
The documented delivery orders issued against this BPA demonstrate sustained procurement activity focused on multiple myeloma and hematologic malignancy treatments. Specific task orders awarded between January 29, 2026 and March 25, 2026 reflect the VA's ongoing operational requirements, ranging from $5,814.24 to $356,543.20 per order and covering various dosage formulations of Pomalyst (2 mg, 3 mg, and 4 mg capsules and tablets), Thalidomide 100 mg formulations, and Camzyos. All delivery orders are structured as firm fixed-price contracts with completion dates spanning through September 30, 2026, providing the Veterans Health Administration with guaranteed access to these immunomodulatory and cardiovascular agents that represent current standards of care in specialized oncology treatment for the veteran population.
Task orders
Show all 37
Quick answers
Who was awarded contract 36E79726A0010?
36E79726A0010 was awarded to Bristol-Myers Squibb Company by National Acquisition Center (Headquarters) on January 16, 2026.
How much is contract 36E79726A0010 worth?
Orders under 36E79726A0010 have obligated $2,235,948. Their combined current value, with exercised options, is $2,241,763. 36E79726A0010's own ceiling is $2,853,029,285.
How many orders have been placed under contract 36E79726A0010?
37 orders have been placed under 36E79726A0010, the latest on August 2, 2026.
Who can order from contract 36E79726A0010?
36E79726A0010 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79726A0010 under another contract?
Yes. 36E79726A0010 is a blanket purchase agreement under 36F79724D0101, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79726A0010 competed?
The extent of competition for 36E79726A0010 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV